Exploring a new pathway for biomarker-based approval of immunotherapies

Josep M. Llovet

doi:10.1038/s41571-023-00731-8

Related publications

Article2021

Immunotherapies for hepatocellular carcinoma

Josep M. Llovet, Florian Castet, Mathias Heikenwälder, Mala K. Maini, Vincenzo Mazzaferro, David J. Pinato, Eli Pikarsky, Andrew X. Zhu, Richard S. Finn

Nature Reviews Clinical Oncology

Article2017

TGF-β oncogenic pathway in HCC: PMEPA1 as a biomarker of treatment response

I.M. Quetglas, Daniela Sia, Jiao Yan, Moe Maeda, M. Castro, Manel Esteller, Josep M. Llovet

Journal of Hepatology

Article2016

Land Development Approval Process Review

Richard M. Ryan, Anthony T. Lawrie

Article2024

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma

Josep M. Llovet, Roser Pinyol, Mark Yarchoan, Amit G. Singal, Thomas U. Marron, Myron Schwartz, Eli Pikarsky, Masatoshi Kudo, Richard S. Finn

Nature Reviews Clinical Oncology

Article2010

GEO-SPADE - A Generic Google Earth-based Framework for Analyzing and Exploring Spatio-temporal Data

Slava Kisilevich, Daniel A. Keim, Lior Rokach